Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (July 2020)
24 slides from Vita Life Sciences's shareholder meeting presentation, Jul 23, 2020
Slide 1: Correction to ASX Announcement - 23 July 2020
For personal use only 23 July 2020 Company Announcements Office Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 Dear Sir/ Madam, CORRECTION TO ASX ANNOUNCEMENT -23 JULY 2020 Vita Life Sciences Limited (ASX: VLS) wishes to advise of a correction to the AGM Presentation issued earlier
Slide 2: AGM Presentation, 31 May 2019
For personal use only 31 May 2019
Slide 3: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer 2
Slide 4: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer 3
Slide 5: For personal use only
Australian & Asia Pacific based pharmaceutical and healthcare over the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements For personal use only 3 major consumer retail brands 700 registered SKUs of vitamins and supplements sold in 7 countries
Slide 6: Full Year 2019 Results
FULL YEAR 2019 RESULTS For personal use only Group sales of $42.4 million for the financial year (FY) ended Dec 2019, an increase of 3% over the previous corresponding period (PCP) of $41.1 million The Group recorded an EBIT of $4.4m, compared to the PCP of $6.2 million (before a non- cash fair valu
Slide 7: Key Financial Charts
KEY FINANCIAL CHARTS Sales EBIT* EPS For personal use only ($’m) (cps) ($’m) 45 7 7 40 6 6 35 5 5 30 4 25 4 20 3 3 5.73 15 2 4.44 2 10 1 5 1 0 0 0 2019 2018 2019 2018 2019 2018 * Underlying FY 2018 EBIT before fair value loss on building revaluation of $1.8m 6
Slide 8: Full Year 2019 Results
FULL YEAR 2019 RESULTS 2019 revenue by geography 2018 revenue by geography For personal use only Other Asia Other Asia 10% 7% Australia Australia Singapore 39% Singapore 40% 14% 17% Asia Asia 61% 60% Malaysia Malaysia 37% 36% Total revenue: $42.4m Total revenue: $41.1m 7
Slide 9: Segment Results: Australia
Sales ($’m) SEGMENT RESULTS AUSTRALIA 16.0 For personal use only 12.0 H2 H2 Sales: $16.7m (2018: $16.4m) Revenue base business grew despite a highly competitive Australian 8.0 market conditions 4.0 H1 H1 New ranging in over 300 new pharmacy stores while increasing new exports trading channels -
Slide 10: Segment Results: Malaysia
Sales ($’m) SEGMENT RESULTS MALAYSIA 16 For personal use only 12 H2 H2 Sales: $15.5m (2018: $14.9m) 8 Revenue base increased by 3.9% due to rejuvenated consumer pull through trade activities 4 H1 H1 Increased distribution of the VitaHealth brand through modern trade pharmacies 0 2019 2018 Herb
Slide 11: Segment Results: Singapore
Sales ($’m) SEGMENT RESULTS SINGAPORE 6 For personal use only H2 H2 Sales $5.9m (2018: $6.9m) 4 Revenue decreased from traditional channels 2 Low consumer sentiment and lower economic activities is weakening the H1 H1 performance 0 Shift towards e-commerce trading by consumers is diluting our
Slide 12: Segment Results: Others
SEGMENT RESULTS OTHERS For personal use only Sales ($’m) Sales $4.3m (2018: $2.9m) 6 Revenue in other markets growth of 49% (PCP) Stronger sales were recorded for Vietnam with marginal improvement in Thailand compared to the PCP 4 Vietnam continues to perform to expectation and is expected to
Slide 13: Strategic Priorities & Outlook
STRATEGIC PRIORITIES & OUTLOOK For personal use only The Board has set a clear strategy which continues to be implemented by management. Some key initiatives in FY 2020 include: • Continued expansion of Herbs of Gold across domestic and export markets • Increased penetration of e-commerce platforms
Slide 14: Strategic Priorities & Outlook - Continued
STRATEGIC PRIORITIES & OUTLOOK-CONTINUED For personal use only The impact of Covid-19 continues to be an evolving situation, which has the potential to disrupt traditional selling channels. That said, the Group has seen a lift in demand for immunity protection products during this period. This deman
Slide 15: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer 14
Slide 16: Ordinary Resolutions
ORDINARY RESOLUTIONS 1. Remuneration Report For personal use only 2. Re-election of Director - Mr Shane Teoh 3. Re-election of Director-Mr Henry Townsing 4. Share buy back 15
Slide 17: Proxy Results
PROXY PROXY’S RESOLUTIONS IN FAVOUR AGAINST ABSTAIN TOTALS DISCRETION For personal use only 1) Adoption of the Remuneration Report 18,053,978 100,700 1,050,319 19,097,600 38,302,597 2) Re-election of Director 28,128,713 92,700 1,637,491 8,443,693 38,302,597 (Mr Shane Teoh) 3) Re-election of Director
Slide 18: Agenda
AGENDA For personal use only 1. Chairman’s Welcome Address 2. Managing Director’s Review 3. Ordinary Resolutions 4. Question & Answer 17
Slide 19: Thank You
THANK YOU For personal use only Contact: Telephone: +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/102 Bath Road, Kirrawee, NSW 2232 18
Slide 20: Appendix
For personal use only APPENDIX 19
Slide 21: Appendix - Profit & Loss
APPENDIX 1 – PROFIT & LOSS Full year ended Dec 2019 2018 For personal use only $’m $’m Revenue 42.4 41.1 EBITDA 5.0 4.8 EBIT 4.4 4.4 Profit before tax 4.4 4.3 Profit after tax 3.1 2.4 EPS (Basic – cents/ share) 5.73 4.44 Dividend (cents / share) 3.75 3.75 20
Slide 22: Appendix - Balance Sheet
APPENDIX 2 – BALANCE SHEET Balance Sheet as at Dec 2019 Dec 2018 $’m $’m For personal use only Current assets 25.8 24.8 Non-current assets 10.7 10.9 Total assets 36.5 35.7 Current liabilities 12.1 11.4 Non-current liabilities 1.9 1.9 Total Liabilities 14.0 13.3 Net Assets 22.5 22.4 21
Slide 23: Appendix - Cash Flow
APPENDIX 3 – CASH FLOW Cash Flow for the year ended 2019 2018 For personal use only $’m $’m Receipts from customers 45.1 44.6 Payments to suppliers and employees 41.2 38.1 Gross operating cash flow 3.9 6.5 Adjusted EBITDA (ex LTIP exp and gain on disposal investments/ 4.8 6.6 revaluation adjustments
Slide 24: Disclaimer
DISCLAIMER For personal use only This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any of